{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:55:06Z","timestamp":1792547706939,"version":"4.5.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metastatic advanced gastric cancer, for which treatment strategies are extremely limited, has a poor prognosis. Complete remission is rare. Patients usually lose the opportunity of therapeutic surgery because the lesions cannot be completely removed, although it can greatly prolong their survival time. Palliative surgery usually suggests bad outcomes. In recent years, the immune checkpoint inhibitor (ICI) nivolumab has shown significant efficacy in the treatment of advanced gastric cancer. However, its applicable conditions and optimal withdrawal time remain controversial owing to its low response rate and high incidence of immune-related adverse events. Herein, we introduce a 66-year-old male patient with advanced gastric cancer with multiple liver metastases who underwent laparoscopic total gastrectomy for acute gastric bleeding. The patient received eight cycles of S-1 plus oxaliplatin (SOX) and switched to eight cycles of SOX plus nivolumab combined regimen in a stable state, later achieving complete remission. There was no recurrence for 32 months after the surgery. This is the first reported case of gastric cancer with multiple liver metastases with long-term complete remission with nivolumab treatment after palliative surgery. The potential mechanism of complete remission was discussed through clinical, genomic, and immune characteristics. The patient had a history of psoriasis and was positive for programmed death ligand 1 (PD-L1), and the interaction of <jats:italic>TP53<\/jats:italic> mutation and <jats:italic>HER-2<\/jats:italic> (-) gene may be associated with complete remission.<\/jats:p>","DOI":"10.3389\/fimmu.2022.908558","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:17:06Z","timestamp":1656508626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery"],"prefix":"10.3389","volume":"13","author":[{"given":"Peilin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","article-title":"Gastric Cancer Treated in 2002 in Japan: 2009 Annual Report of the JGCA Nationwide Registry","volume":"16","author":"Nashimoto","year":"2013","journal-title":"Gastric Canc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2017.17.e23","article-title":"Comparison of the Differences in Survival Rates Between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: A Single-Institution Study of 5,507 Patients in Korea","volume":"17","author":"Kim","year":"2017","journal-title":"J Gastric Canc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12718","article-title":"Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer","volume":"36","author":"Arigami","year":"2022","journal-title":"In Vivo"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07790-1","article-title":"Curative-Intent Surgery for Stage IV Advanced Gastric Cancer: Who can Undergo Surgery and What Are the Prognostic Factors for Long-Term Survival","volume":"26","author":"Sato","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-017-0738-1","article-title":"The Long-Term Survival of Stage IV Gastric Cancer Patients With Conversion Therapy","volume":"21","author":"Yamaguchi","year":"2018","journal-title":"Gastric Canc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10120-011-0040-6","article-title":"New Japanese Classifications and Treatment Guidelines for Gastric Cancer: Revision Concepts and Major Revised Points","volume":"14","author":"Sano","year":"2011","journal-title":"Gastric Canc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70436-4","article-title":"Management of Gastric Cancer in Asia: Resource-Stratified Guidelines","volume":"14","author":"Shen","year":"2013","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single non-Curable Factor (REGATTA): A Phase 3, Randomised Controlled Trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0040","article-title":"In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in non-Human Primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and are Functionally Impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci74894","article-title":"Tumor-Specific Cytotoxic T Lymphocyte Activity Determines Colorectal Cancer Patient Prognosis","volume":"125","author":"Reissfelder","year":"2015","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.3390\/cancers13246158","article-title":"Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids","volume":"13","author":"Chakrabarti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and Adaptive Immune Cells in the Tumor Microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.12.006","article-title":"A PD1 Targeted Nano-Delivery System Based on Epigenetic Alterations of T Cell Responses in the Treatment of Gastric Cancer","volume":"24","author":"Hu","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31827-5","article-title":"Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","article-title":"Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients With Metastatic Gastric Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro","year":"2019","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"432484734","DOI":"10.1177\/1758835919867522","article-title":"Late-Line Treatment in Metastatic Gastric Cancer: Today and Tomorrow","volume":"11","author":"Smyth","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01862","article-title":"Prognostic Factors to Predict the Survival in Patients With Advanced Gastric Cancer Who Receive Later-Line Nivolumab Monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC)","volume":"11","author":"Tanaka","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","article-title":"Predictive Factors for Hyperprogressive Disease During Nivolumab as Anti-PD1 Treatment in Patients With Advanced Gastric Cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Canc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/cam4.4461","article-title":"The New Prognostic Score for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multi-Institutional Cohort Study","volume":"5","author":"Okumura","year":"2021","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e002879","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-Associated DRESS in a Genetic Susceptible Individual","volume":"9","author":"Ai","year":"2021","journal-title":"J Immunother Canc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint Inhibitors for Gastroesophageal Cancers: Dissecting Heterogeneity to Better Understand Their Role in First-Line and Adjuvant Therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE Guidelines for Case Reports: Explanation and Elaboration Document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12957-020-01954-0","article-title":"Conversion Surgery for Stage IV Gastric Cancer With a Complete Pathological Response to Nivolumab","volume":"18","author":"Matsumoto","year":"2020","journal-title":"A Case Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-020-00433-3","article-title":"A Long-Term Survival Case of Unresectable Gastric Cancer With Multidisciplinary Therapy Including Immunotherapy and Abscopal Effect","volume":"9","author":"Kuhara","year":"2020","journal-title":"Int Cancer Conf J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143433","article-title":"The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer","volume":"13","author":"Ribatti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13104-016-2153-9","article-title":"Immune Checkpoint Inhibitors and Response Analysis: A Tough Challenge","volume":"9","author":"Bearz","year":"2016","journal-title":"A Case Rep BMC Res Notes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1295","article-title":"Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards","volume":"8","author":"Sundar","year":"2018","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","article-title":"Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma","volume":"8","author":"Pectasides","year":"2018","journal-title":"Cancer Discov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000507219","article-title":"Response Rate and Prognostic Impact of Salvage Chemotherapy After Nivolumab in Patients With Advanced Gastric Cancer","volume":"98","author":"Arigami","year":"2020","journal-title":"Oncology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14187","article-title":"Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-Treated Metastatic Gastric Cancer","volume":"40","author":"Kato","year":"2020","journal-title":"Anticancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s305039","article-title":"Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man With Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review","volume":"14","author":"Tian","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in Previously Treated Advanced Gastric Cancer (ATTRACTION-2): 3-Year Update and Outcome of Treatment Beyond Progression With Nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Canc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0519-7","article-title":"Programmed Cell Death Protein 1 Expression Is an Independent Prognostic Factor in Gastric Cancer After Curative Resection","volume":"19","author":"Eto","year":"2016","journal-title":"Gastric Canc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540","article-title":"Safety and Efficacy of Nivolumab in Combination With S-1\/Capecitabine Plus Oxaliplatin in Patients With Previously Untreated, Unresectable, Advanced, or Recurrent Gastric\/Gastroesophageal Junction Cancer: Interim Results of a Randomized, Phase II Trial (ATTRACTION-4)","volume":"30","author":"Boku","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01124","article-title":"Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability as A Biomarker in Gastric Cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12885-021-09115-6","article-title":"Checkpoint Inhibitors in Metastatic Gastric and GEJ Cancer: A Multi-Institutional Retrospective Analysis of Real-World Data in a Western Cohort","volume":"22","author":"Schlintl","year":"2022","journal-title":"BMC Canc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759250","article-title":"A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive Molecular Characterization of Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-020-00432-4","article-title":"A Case of Multiple Metastatic Gastric Cancer With Primary Lesion Vanished After Administrating Nivolumab, and the Effect Remains Even After Discontinuance of Therapy","volume":"9","author":"Doi","year":"2020","journal-title":"Int Cancer Conf J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s13256-021-03200-x","article-title":"Confirmed Complete Response to Nivolumab for Advanced Gastric Cancer With Peritoneal Dissemination: A Case Report","volume":"15","author":"Takami","year":"2021","journal-title":"J Med Case Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-Infiltrating Lymphocytes in the Immunotherapy Era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0436","article-title":"Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures","volume":"7","author":"Zeng","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4180517","article-title":"PD-L1 Expression and CD8 T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer","volume":"2018","author":"Wang","year":"2018","journal-title":"J Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16407","article-title":"The PD-1, PD-L1 Expression and CD3+ T Cell  Infiltration in Relation to Outcome in Advanced Gastric Signet-Ring Cell Carcinoma, Representing a Potential Biomarker for Immunotherapy","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000326","article-title":"Four Distinct Immune Microenvironment Subtypes in Gastric Adenocarcinoma with Special Reference to Microsatellite Instability","volume":"3","author":"Cho","year":"2018","journal-title":"ESMO open"},{"key":"B52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","article-title":"Prognostic Impacts of the Combined Positive Score and the Tumor Proportion Score for Programmed Death Ligand-1 Expression by Double Immunohistochemical Staining in Patients With Advanced Gastric Cancer","volume":"23","author":"Yamashita","year":"2020","journal-title":"Gas Canc"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e003580","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, Open-Label, Phase 2 Study of Andecaliximab Plus Nivolumab Versus Nivolumab Alone in Advanced Gastric Cancer Identifies Biomarkers Associated With Survival","volume":"9","author":"Shah","year":"2021","journal-title":"J Immunother Canc"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.120071","article-title":"Crystal Structure of Folliculin Reveals a hidDENN Function in Genetically Inherited Renal Cancer","volume":"2","author":"Nookala","year":"2012","journal-title":"Open Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00688","article-title":"Folliculin Interacts With Rab35 to Regulate EGF-Induced EGFR Degradation","volume":"8","author":"Zheng","year":"2017","journal-title":"Front Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21313","article-title":"MUT-TP53 2.0: A Novel Versatile Matrix for Statistical Analysis of TP53 Mutations in Human Cancer","volume":"31","author":"Soussi","year":"2010","journal-title":"Hum Mutat"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749204","article-title":"Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in A Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.908558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:17:13Z","timestamp":1656508633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.908558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2022.908558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.908558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"article-number":"908558"}}